Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II axitinib in recurrent/metastatic salivary gland cancers of the upper aerodigestive tract
2014-003227-21Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in salivary gland cancer (SGC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Objective response rate (ORR) by RECIST 1.1. Started Aug 2014; status: completed.
02
Drugs
axitinib
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on 2014-003227-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003227-21.